PT  - JOURNAL ARTICLE
AU  - Waschkies, Konrad F.
AU  - Soch, Joram
AU  - Darna, Margarita
AU  - Richter, Anni
AU  - Altenstein, Slawek
AU  - Beyle, Aline
AU  - Brosseron, Frederic
AU  - Buchholz, Friederike
AU  - Butryn, Michaela
AU  - Dobisch, Laura
AU  - Ewers, Michael
AU  - Fliessbach, Klaus
AU  - Gabelin, Tatjana
AU  - Glanz, Wenzel
AU  - Goerss, Doreen
AU  - Gref, Daria
AU  - Janowitz, Daniel
AU  - Kilimann, Ingo
AU  - Lohse, Andrea
AU  - Munk, Matthias H.
AU  - Rauchmann, Boris-Stephan
AU  - Rostamzadeh, Ayda
AU  - Roy, Nina
AU  - Spruth, Eike Jakob
AU  - Dechent, Peter
AU  - Heneka, Michael T.
AU  - Hetzer, Stefan
AU  - Ramirez, Alfredo
AU  - Scheffler, Klaus
AU  - Buerger, Katharina
AU  - Laske, Christoph
AU  - Perneczky, Robert
AU  - Peters, Oliver
AU  - Priller, Josef
AU  - Schneider, Anja
AU  - Spottke, Annika
AU  - Teipel, Stefan
AU  - Düzel, Emrah
AU  - Jessen, Frank
AU  - Wiltfang, Jens
AU  - Schott, Björn H.
AU  - Kizilirmak, Jasmin M.
TI  - Big Five, self-reported depression, and anxiety are predictive for Alzheimer’s disease
AID  - 10.1101/2022.11.30.22282930
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.30.22282930
4099  - http://medrxiv.org/content/early/2022/12/01/2022.11.30.22282930.short
4100  - http://medrxiv.org/content/early/2022/12/01/2022.11.30.22282930.full
AB  - Objectives The main goal of machine learning approaches to classify people into healthy, increased Alzheimer’s disease (AD) risk, and AD is the identification of valuable predictors for valid classification, prediction of conversion, and automatization of the process. While biomarkers from cerebrospinal fluid (CSF) are the best-established predictors for AD, other less invasive, easy-to-assess candidate predictors have been identified. Here, we evaluated the predictive value of such less invasive, predictors separately and in different combinations for classification of healthy controls (HC), subjective cognitive decline (SCD), mild cognitive impairment (MCI), and mild AD.Methods We evaluated the predictive value of personality scores, geriatric anxiety and depression scores, a resting-state functional magnetic resonance imaging (fMRI) marker (mPerAF), apoliprotein E (ApoE), and CSF markers (tTau, pTau181, Aβ42/40 ratio) separately and in different combinations in multi-class support vector machine classification. Participants (189 HC, 338 SCD, 132 MCI, 74 mild AD) were recruited from the multi-center DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE).Results HC were best predicted by a feature set comprised of personality, anxiety, and depression scores, while participants with AD were best predicted by a feature set containing CSF markers. Both feature sets had equally high overall decoding accuracy. However, all assessed feature sets performed relatively poorly in the classification of SCD and MCI.Conclusion Our results highlight that SCD and MCI are heterogeneous groups, pointing out the importance of optimizing their diagnosis criteria. Moreover, CSF biomarkers, personality, depression, and anxiety indicate complementary value for class prediction, which should be followed up on in future studies.Key PointsUsing multi-class support vector machine, we compared the predictive value of well-established versus non-invasive, easy-to-assess candidate variables for classification of participants with healthy cognition, subjective cognitive decline, mild cognitive impairment, and mild Alzheimer’s disease.Personality traits, geriatric anxiety and depression scores, resting-state mPerAF, ApoE genotype, and CSF markers were comparatively evaluated both separately and in different combinations.Predictive accuracy was similarly high for a combination of personality, anxiety and depression scores as for CSF markers.Both established as well as candidate variables performed poorly in classifying SCD and MCI, highlighting heterogenous causes of those cognitive states.CSF biomarkers and extended personality measures show complementary value for class prediction, which should be followed up on in future studies.Competing Interest StatementF. Jessen received fees for consultations and presentations between 2019 and 2022 from AC Immune, Biogen, Danone/Nutricia, Eisai, GE Healthcare, Grifols, Janssen, Lilly, MSD, Novo Nordisk, and Roche. E. Düzel is cofounder of neotiv GmbH. The remaining authors report no disclosures relevant to the manuscript.Clinical Protocols https://drks.de/search/de/trial/DRKS00007966 Funding StatementThe study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen [DZNE]), reference number BN012.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by Institutional Review Boards of all participating study centers of the DZNE. The process was led and coordinated by the ethical committee of the medical faculty of the University of Bonn (registration number 117/13).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll scripts used to perform the analyses are available under https://github.com/jmkizilirmak/DELCODE162. Data can be made available to cooperation partners of the DZNE after setting up appropriate data sharing contracts.AβAmyloid betaADAlzheimer’s diseaseaMCIamnestic mild cognitive impairmentANOVAanalysis of varianceBFIBig Five InventoryBFI-10Big Five Inventory 10-item short formBOLDblood oxygenation level-dependentCERADConsortium to Establish a Registry for Alzheimer’s DiseaseCAclass accuracyCIconfidence intervalCSFcerebrospinal fluidCVcross-validationDAdecoding accuracyDMNdefault mode networkDELCODEDZNE-Longitudinal Cognitive Impairment and Dementia StudyDZNEDeutsches Zentrum für neurodegenerative ErkrankungenEPIecho-planar imagingfMRIfunctional magnetic resonance imagingFWHMfull width at half maximumGAI-SFGeriatric Anxiety Inventory, Short FormGDSGeriatric Depression ScaleHChealthy controlsHzHertzMCImild cognitive impairmentNIANational Institute on AgingMMSEMini Mental Status ExaminationMNIMontreal Neurological InstitutemPerAFmean percent amplitude of fluctuationMPRAGEMagnetization Prepared Rapid Gradient EchoMRImagnetic resonance imagingNEO PI-RRevised NEO Personality InventoryPerAFpercent amplitude of fluctuationpTau181phosphorylated tau181ROIregion of interestrs-fMRIresting-state functional magnetic resonance imagingSCDsubjective cognitive declineSDstandard deviationSPMStatistical Parametric MappingSVCsupport vector classificationSVMsupport vector machineTEecho timeTRtime to repetitiontTautotal tauVDMvoxel-displacement mapyrsyears